Corporate Presentation September 2025 1 2 Building a Leading Allergy and Immunology Company Transforming science that WORKS… …into therapies that patients WANT. HEREDITARY ANGIOEDEMA (HAE) FLS This presentation contains forward-looking statements within the meaning of applicable securities laws and regulations including, but not limited to, statements regarding: the expected timing of receipt of topline results from the navenibart ALPHA-ORBIT Phase 3 trial; the goals and objectives of the ALPHA-ORBIT Phase ...

Astria Therapeutics (ATXS) 2025 Conference September 04, 2025 03:20 PM ET Speaker1Great. Good afternoon, everyone, and welcome to the next session at the Cantor Global Health Care Conference. I'm Steve Seedhouse on the Cantor Biotech team, really glad to be joined by our next participating company, Astria Therapeutics, an exciting company that we launched coverage on when we came to Cantor. It's been a privilege to cover so far, and looking forward to all the upcoming progress. I'm joined on stage by CEO Ji ...